Gelsolin Agent for Decompression Sickness Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for decompression sickness, such as hyperbaric oxygen therapy, are limited by the need for isolation, which hinders medical personnel's ability to monitor and treat patients effectively, and there is a lack of understanding of the relationship between plasma protein gelsolin and the stress of high pressure and decompression.
Innovation Solution
A method involving the detection of specific microparticle signatures, including IL-1β, Ly6G, and CD66b, to diagnose and treat decompression sickness and other related conditions by administering a gelsolin agent, which reduces the severity and risk of these conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hyperbaric oxygen therapy is used to treat decompression sickness, then treatment effectiveness is improved, but patient isolation requirements worsen medical monitoring capability
Solution Approach 1:
The treatment approach is segmented into two phases: (1) administration of gelsolin agent to prevent/treat decompression sickness, and (2) optional hyperbaric oxygen therapy for severe cases. This segmentation allows most patients to be treated without isolation, while only severe cases require hyperbaric chamber treatment, thereby improving overall monitoring capability while maintaining treatment effectiveness for the majority of patients.
Solution Approach 2:
Gelsolin agent is administered as a preliminary action before decompression sickness fully develops or worsens. By giving the agent prophylactically or early in the treatment course, the need for subsequent hyperbaric oxygen therapy is reduced, allowing patients to be treated in ordinary medical settings with full monitoring capability rather than isolated hyperbaric chambers.
2Measurement precision
If microparticle detection methods are developed to identify decompression sickness, then diagnostic precision is improved, but device complexity increases
Solution Approach 1:
Microparticles serve as an intermediary marker that indirectly indicates the presence of decompression sickness. Instead of directly detecting complex physiological changes in patients, the system detects microparticles in blood samples, which are easier to measure with standard laboratory equipment. This intermediary approach achieves high diagnostic precision using existing, relatively simple devices rather than requiring complex new detection systems.
Solution Approach 2:
The detection method replaces complex mechanical/physiological monitoring systems with a biochemical assay approach. By substituting direct physiological measurement with microparticle detection in blood samples, the system achieves comparable or superior diagnostic precision using standard laboratory equipment rather than complex specialized devices.
Data Source
AI summary
The present invention relates to compositions and methods for identifying and treating signature MP-associated diseases and conditions in subjects. In particular, treatment methods of the invention include administering a gelsolin agent to produce a therapeutic effect against a signature MP-associated disease or condition in a subject.